TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Autolus Therapeutics Plc
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL®, a CAR T cell therapy developed by Autolus Therapeutics, as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in England and Wales.

Insights
UBER   positive

Included in the author's personal investment portfolio


AUTL   positive

Company received NICE recommendation for its innovative CAR T cell therapy, indicating potential market expansion and clinical validation of its treatment